BENSALEM, Pa.–(BUSINESS WIRE)–Healthcare Services Group, Inc. (NASDAQ:HCSG) (the “Company”) reported for the three months ended June 30, 2022 revenue of $424.9 million and net income of $6.8 million, or $0.09 per basic and diluted common share. The Company’s Board of Directors declared a quarterly cash dividend of $0.21375 per common share, the 76th consecutive increase … [Read more…]
HANOVER, Germany–(BUSINESS WIRE)–Cardior Pharmaceuticals, a clinical-stage biotech company developing non-coding RNA (ncRNA)-based therapeutics for patients with cardiac diseases, today announced the dosing of the first patient in their multicenter Phase 2 trial assessing efficacy and safety of CDR132L in 280 patients with reduced left ventricular ejection fraction after myocardial infarction (HF-REVERT). CDR132L is an oligonucleotide-based … [Read more…]
Second quarter GAAP net income was $6.79 per share, including net negative adjustment items of $1.25 per share. Adjusted net income was $8.04* per share. Operating revenue grew 15.6% over the prior year quarter to $38.5 billion. Operating gain grew 13.7% over the prior year quarter to $2.4 billion. Medical enrollment increased 2.7 million members … [Read more…]
Mom and Dad Want Independence and Peace of Mind at Home? Cherry And NIH Study To Help REDWOOD CITY, Calif.–(BUSINESS WIRE)–Cherry Labs today announced they received a grant from the National Institutes of Health (NIH) and are embarking on a study to help maintain independence for older adults using their AI-driven Cherry Home technology. Cherry … [Read more…]
New data emphasizes the utility of the VeriStrat® Proteomic Test to identify patients likely to benefit from Immune Checkpoint Inhibitors BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Young Kwang Chae, MD, MPH, MBA, Associate Professor of Medicine (Hematology and Oncology) … [Read more…]
– Proceeds to Support Clinical Development of Lead CNS & Liver Programs; IND for Dravet Syndrome is Anticipated by Mid-2023 – New Capital Will Also Fuel Expansion of CAMP4’s regRNA Actuating Platform™, Harnessing the Power of Regulatory RNA to Upregulate Gene Expression – Funding Round Led by Enavate Sciences, a Portfolio Company of Patient Square … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “6-Hour Virtual Seminar on Master Class for the HIPAA Officer: Protecting Patient Information and Implementing Today’s Privacy, Security, and Breach Regulations” webinar has been added to ResearchAndMarkets.com’s offering. Overview: The session begins with overview of the HIPAA regulations and then continues with presentation of the specifics of the Privacy Rule, such as Individual … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Building a Vendor Qualification Program for FDA Regulated Industries” training has been added to ResearchAndMarkets.com’s offering. This course will provide detailed explanations and examples for Building a Vendor Qualification Program for FDA Regulated Industry. With today’s pharmaceutical market, raw materials, Active Pharmaceutical Ingredients (API), Containers & Closures, inactive or excipients and other components … [Read more…]
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that after 5 years of follow-up, Leber Hereditary Optical Neuropathy (LHON) subjects treated with LUMEVOQ® (GS010) continued to experience significantly improved … [Read more…]
Five years since its creation, ATLATL has served more than 100 early-stage biotechs and projects. SHANGHAI–(BUSINESS WIRE)–#Shanghai–Celebrating its 5th anniversary, ATLATL proclaims that it will continue contributing to the rapid growth of the life sciences sector in China. The ATLATL Center for Innovation & Research is a biopharmaceutical research-based open innovation platform committed to building … [Read more…]
